<a href="https://laohu8.com/S/ALUR">Allurion Technologies</a> Submits Final PMA Module to FDA, Strengthening Case for Allurion Balloon Approval
Allurion Technologies Holdings Inc., a leader in metabolically healthy weight loss solutions, has announced the submission of the fourth and final module of its Pre-Market Approval (PMA) application to the U.S. Food & Drug Administration (FDA). This submission includes additional supportive analyses from the pivotal AUDACITY Study, successfully meeting both pre-specified co-primary endpoints. The AUDACITY Study is noted for being the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. Dr. Shantanu Gaur, Founder and CEO of Allurion, expressed enthusiasm about the submission, emphasizing the analyses strengthen their positive topline data. The company is now looking forward to collaborating with the FDA towards obtaining approval for the Allurion Balloon.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250707165712) on July 07, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。